Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
pharmaphorum2d
Enhertu gets first okay for HER2-ultralow breast cancer
Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...
Woman mistook symptoms for common cold before being told she has year to live
Nicola Heart, from New York, US, was diagnosed with incurable breast cancer after doctors discovered the disease had spread ...
pharmaphorum1d
Roche gets FDA approval for HER2 breast cancer diagnostic
The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU. The ...
Woman who had 'cold she couldn't shake' told she had less than a year to live
Nicola Heart, 37, was diagnosed with metastatic breast cancer after years of debilitating symptoms and given just months to ...
Woman who had 'cold she couldn't shake' told she had year to live
A 37-year old woman was told she had less than a year to live after doctors said she had incurable breast cancer. Nicola ...
PharmiWeb2d
New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings
New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...
Study suggests exercise could reduce breast cancer recurrence
Exercise could potentially reduce the recurrence rate of breast cancer, new research from Edith Cowan University (ECU) has ...
Breast cancer screening is ripe for change. We need to assess a woman’s risk – not just her age
A fundamental shake-up of how we screen women for breast cancer could save more lives from the disease. Here are some options ...
Delay of more than 42 days for breast cancer surgery raises death risk for certain subtypes, study finds
Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 ...
EurekAlert!2d
ECU study finds exercise could reduce breast cancer recurrence
Exercise could potentially reduce the recurrence rate of breast cancer, new research from Edith Cowan University (ECU) has found.